NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This is an open label, phase I/II clinical trial to evaluate the efficacy and safety of 2
cycles of durvalumab without (Arm A) or with (Arm B) tremelimumab in association with ddMVAC
as neoadjuvant therapy in patients with MIUC.